The biotech sells blood disorders treatment, Casgevy.CRISPR Therapeutics (CRSP 2.50%) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, on optimism about the potential approval of its first gene editing therapy. That candidate eventually won the regulatory nod and is commercialized as Casgevy, a gene editing treatment for blood disorders.But the biotech stock has spent recent years declining, and though it's rebounded somewhat this year, it still is down more than 60 ...